NanoViricides Advances MPox Treatment with Adaptive Clinical Trial Design
NanoViricides, Inc. nears finalization of an adaptive clinical trial protocol for NV-387, a potential first-in-class treatment for MPox, highlighting its significance amid limited effective therapies.
NanoViricides, Inc. (NYSE American: NNVC) has announced the near-finalization of its adaptive clinical trial protocol for NV-387, targeting MPox Clade Ia and Ib in the Democratic Republic of Congo. This two-part Phase II trial aims to evaluate the safety, dosing, and efficacy of NV-387 oral gummies, designed for easier administration in patients suffering from painful oral lesions. NV-387 stands as a potential breakthrough, possibly becoming the first drug to demonstrate clinical efficacy against an orthopoxvirus in humans.
The development of NV-387 is particularly noteworthy given the limitations of existing treatments such as Tecovirimat and Brincidofovir, which have shown poor efficacy or adverse effects in trials. With Clade 1b MPox remaining a transmissible epidemic threat in Africa and posing a potential risk to Western nations, the success of NV-387 could have significant implications for global health. NanoViricides plans to pursue regulatory approvals across Africa, the U.S., and globally, including for smallpox, should the trial outcomes be favorable.
For more details on the announcement, visit https://ibn.fm/83cFs.